The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Medpage Today on MSN3d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, ...
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
With a capital investment of US$66.1 million and 63 new jobs created, this expansion includes the addition of 63,000 square feet of administrative space and more than 28,000 square feet of laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback